Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.

The announcements were made during high-level industry interactions led by the state government, reflecting strong investor confidence in Odisha’s policy framework and industrial infrastructure.

The proposed investments cover pharmaceutical formulations, bulk drugs, medical devices, and allied healthcare manufacturing.

Chief Minister Mohan Charan Majhi said the inflow of investments underscores Odisha’s commitment to building a competitive and innovation-driven industrial ecosystem. “Odisha is focused on creating an enabling environment for pharma and medtech companies through robust infrastructure, transparent governance, and investor-friendly policies.”

Beyond manufacturing scale-up, the investments are expected to drive research, innovation, and technology transfer in the pharma and medtech sectors.

Industries Minister Sampad Chandra Swain highlighted that targeted incentives and sector-specific parks are helping attract long-term investments. “With dedicated industrial clusters and fast-track approvals, Odisha is positioning itself as a preferred destination for pharma and medical device manufacturing.”

He added that the government is working closely with investors to ensure timely project execution and seamless operational support.

Looking ahead, the Odisha government plans to convert these commitments into on-ground projects through continued industry engagement, reinforcing the state’s alignment with national initiatives such as Make in India and Atmanirbhar Bharat, while building a sustainable healthcare manufacturing ecosystem.

Related Posts

Minister JP Nadda launches drug registry to standardise medicine-related information

Union minister of health and family welfare, Jagat Prakash Nadda launched the Drug Registry as a unified and standardised digital platform for drug-related information to address the issues including confusion…

Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged its member pharma companies to implement the Voluntary Code of Conduct (VCC) introduced by the Narcotics Control Bureau (NCB) to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Minister JP Nadda launches drug registry to standardise medicine-related information

Minister JP Nadda launches drug registry to standardise medicine-related information

Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

Govt review finds no common thread in post-delivery deaths

Gurgaon call centre busted for cheating people with fake weight-loss products, 3 women held

Gurgaon call centre busted for cheating people with fake weight-loss products, 3 women held

Madhya Pradesh toddler loses vision after doctor administers drops, probe underway

Madhya Pradesh toddler loses vision after doctor administers drops, probe underway

CDSCO Mandates SUGAM Portal for Post-Approval Changes (PAC) to Vaccine and Anti-Sera Import Licences

CDSCO Mandates SUGAM Portal for Post-Approval Changes (PAC) to Vaccine and Anti-Sera Import Licences